/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

J

Jaap Verweij

Leiden University Medical Center(NL)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

885

Papers

70.5K

Citations

115

h-index

527

i10-index

Jaap Verweij is an academic researcher from Leiden University Medical Center. The author has contributed to research in topics: Cancer therapeutics and mechanisms & Cancer Treatment and Pharmacology & Sarcoma Diagnosis and Treatment. The author has an h-index of 115, co-authored 753 publications.

Research Topics

Cancer therapeutics and mechanisms Cancer Treatment and Pharmacology Sarcoma Diagnosis and Treatment Gastrointestinal Tumor Research and Treatment Neutropenia and Cancer Infections

Papers by this author

works

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

2004 · The Lancet · 1,659 citations

https://doi.org/10.1016/s0140-6736(04)17098-0

Jaap Verweij Paolo G. Casali John Zalcberg A. Lecesne

Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study

2010 · The Lancet Oncology · 649 citations

https://doi.org/10.1016/s1470-2045(10)70071-1

Rolf D. Issels Lars H. Lindner Jaap Verweij Peter Wust

Initial and Late Resistance to Imatinib in Advanced Gastrointestinal Stromal Tumors Are Predicted by Different Prognostic Factors: A European Organisation for Research and Treatment of Cancer–Italian Sarcoma Group–Australasian Gastrointestinal Trials Group Study

2005 · Journal of Clinical Oncology · 279 citations

https://doi.org/10.1200/jco.2005.11.601

M. van Glabbeke Jaap Verweij Paolo G. Casali Axel Le Cesne

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

2007 · British Journal of Cancer · 230 citations

https://doi.org/10.1038/sj.bjc.6604108

F. Eskens Constantijne H. Mom André Planting Jourik A. Gietema

Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels

2017 · Journal of Clinical Oncology · 189 citations

https://doi.org/10.1200/jco.2016.71.0228

Paolo G. Casali John Zalcberg Axel Le Cesne Peter Reichardt

A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours

2000 · British Journal of Cancer · 96 citations

https://doi.org/10.1054/bjoc.2000.1160

L. Pronk P. Vasey Alex Sparreboom Bruno Reigner

Research topics

topics

Cancer therapeutics and mechanisms

Cancer Treatment and Pharmacology

Sarcoma Diagnosis and Treatment

Gastrointestinal Tumor Research and Treatment

Neutropenia and Cancer Infections

Chat about Author

Papers

Chat

Click to start Chat